stockrowNeurocrine Biosciences, Inc.
NBIX Healthcare Drug Manufacturers Specialty & Generic
Neurocrine Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 21.4% from fiscal 2024.
- Revenue
- +41.2%
- EPS
- −3.67%
- Free cash flow
- +79.0%
Quarter to September 2026, against a year earlier
Follow NBIX
Alert me
Neurocrine Biosciences, Inc. (NBIX) Operating cash flow
Neurocrine Biosciences, Inc.'s operating cash flow for fiscal 2025 was $782.7M, up 31.5% from $595.4M in fiscal 2024. Over the twelve months to 30 September 2026 it was $1.1B. Over the past ten years it has ranged from −$106.2M (fiscal 2016) to $782.7M (fiscal 2025) — the current reading is the highest in ten years. Operating cash flow has risen for 9 consecutive fiscal years. Neurocrine Biosciences, Inc. ranks 7th of 84 Drug Manufacturers Specialty & Generic companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | $782.7M | 31.46% |
| FY2024 | $595.4M | 52.71% |
| FY2023 | $389.9M | 14.88% |
| FY2022 | $339.4M | 32.32% |
| FY2021 | $256.5M | 12.25% |
| FY2020 | $228.5M | 55.44% |
| FY2019 | $147.0M | 44.97% |
| FY2018 | $101.4M | — |
| FY2017 | −$94.3M | — |
| FY2016 | −$106.2M | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Sep 2026 | $395.2M | 189.74% |
| Jun 2026 | $136.4M | (6.45%) |
| Mar 2026 | $145.8M | (62.46%) |
| Dec 2025 | $388.4M | 70.73% |
| 43 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| HLN Haleon PLC Sponsored ADR compare | $4.8B |
| ZTS Zoetis Inc. compare | $2.8B |
| VTRS Viatris Inc. compare | $2.5B |
| UTHR United Therapeutics Corporation compare | $1.4B |
| NBIX Neurocrine Biosciences, Inc. | $1.1B |
| ELAN Elanco Animal Health Incorporated compare | $617.0M |
| RDY Dr. Reddy's Laboratories Ltd compare | $313.0M |
| ALKS Alkermes plc compare | $243.0M |
| KNSA Kiniksa Pharmaceuticals International, plc compare | $198.8M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on NBIX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement